We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates
Read MoreHide Full Article
Agios Pharmaceuticals (AGIO - Free Report) receives royalties on net sales of Idhifa (enasidenib) from collaboration partner Celgene. The company received $26.4 million of collaboration revenue and $1.6 million of royalty revenue from net sales of Idhifa in United States.
In July, Agios announced the FDA approval of Tibsovo for the treatment of patients with relapsed or refractory acute myeloid leukemia (“AML”) with an isocitrate dehydrogenase-1(IDH-1) mutation. The approval came a month earlier than the action date of Aug 21, 2018, which is a huge boost to the company as it represents immense commercial potential in the AML market.
Meanwhile, a regulatory filing for the Tibsovo in the EU is expected during the fourth quarter of 2018 for the same indication.
Agios’ earnings performance so far has been dismal with the company beating expectations in one of the last four reported quarters and missing in the other three. Overall, the company has delivered an average negative surprise of 5.02%.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Loss Wider: Agios posted narrower-than-expected loss in the second quarter of 2018. Our consensus called for a loss of $1.62 per share, and the company reported a loss of $1.19. The loss reported was also narrower than the year ago loss of $1.78.
Revenues Beat: Revenues in the reported quarter also came hugely above expectations. Agios posted revenues of approximately $40.4 million, compared to our consensus estimate of $12.09 million. The revenues increased a mammoth 257.5% from year ago figure of $11.3 million.
Key Stats: Research & development expenses were up 8.6% year over year to $86.7 million. General and administrative expenses increased 65.1% year over year to $26.6 million.
Share Price Impact: Shares were up 2.3% in pre-market trading.
Check back later for our full write up on AGIO earnings report later!
Agios Pharmaceuticals, Inc. Price and EPS Surprise
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates
Agios Pharmaceuticals (AGIO - Free Report) receives royalties on net sales of Idhifa (enasidenib) from collaboration partner Celgene. The company received $26.4 million of collaboration revenue and $1.6 million of royalty revenue from net sales of Idhifa in United States.
In July, Agios announced the FDA approval of Tibsovo for the treatment of patients with relapsed or refractory acute myeloid leukemia (“AML”) with an isocitrate dehydrogenase-1(IDH-1) mutation. The approval came a month earlier than the action date of Aug 21, 2018, which is a huge boost to the company as it represents immense commercial potential in the AML market.
Meanwhile, a regulatory filing for the Tibsovo in the EU is expected during the fourth quarter of 2018 for the same indication.
Agios’ earnings performance so far has been dismal with the company beating expectations in one of the last four reported quarters and missing in the other three. Overall, the company has delivered an average negative surprise of 5.02%.
Currently, Agios has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Loss Wider: Agios posted narrower-than-expected loss in the second quarter of 2018. Our consensus called for a loss of $1.62 per share, and the company reported a loss of $1.19. The loss reported was also narrower than the year ago loss of $1.78.
Revenues Beat: Revenues in the reported quarter also came hugely above expectations. Agios posted revenues of approximately $40.4 million, compared to our consensus estimate of $12.09 million. The revenues increased a mammoth 257.5% from year ago figure of $11.3 million.
Key Stats: Research & development expenses were up 8.6% year over year to $86.7 million. General and administrative expenses increased 65.1% year over year to $26.6 million.
Share Price Impact: Shares were up 2.3% in pre-market trading.
Check back later for our full write up on AGIO earnings report later!
Agios Pharmaceuticals, Inc. Price and EPS Surprise
Agios Pharmaceuticals, Inc. Price and EPS Surprise | Agios Pharmaceuticals, Inc. Quote
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>